Cardiovascular/Renal Drugs EC Flashcards
Drugs to treat Essential Hypertension
Diuretics
ACE inhibitors
ARBs
Ca channel blockers
Drugs to treat CHF
Diuretics ACE inhibitors ARBs Beta-blockers (compensated CHF only) K-sparing diuretics
DM hypertension treatment
ACE inhibitors ARBs Ca channel blockers Diuretics Beta-blockers Alpha blockers
Nifedipine, Amlodipine, Verapamil, Diltiazem (MOA, Use, Tox)
Block voltage gated L-type Ca channels (reduce contractility in cardiac and smooth muscle)
Amlodipine and Nifedipine esp in Smooth Muscle
Verapamil and Diltiazem esp in Heart
Cardiac depression
AV block
Peripheral edema
Hydralazine (MOA, Use, Tox)
Increase cGMP = vasodilates arterioles
Severe hypertension
CHF
First line for HTN in pregnancy (w/ methyldopa)
Compensatory tachycardia (given w/ beta blocker to prevent - contra. in CAD)
Fluid retention
Lupus-like syndrome
Malignant hypertension treatment (Drugs, Use, Tox)
Nitroprusside (increase cGMP via NO release)
~can cause cyanide toxicity
Fenoldopam (D1 agonist - Lower BP and increased natriuresis)
Nitroglycerin, Isosorbide, Dinitrate (MOA, Use, Tox)
Increase cGMP via NO release
Dilates VEINS
Angina
Pulmonary edema
Reflex tachycardia
Hypotension
“Monday disease” (tolerance during week, loss of tolerance over weekend results in tachycardia, dizziness, and headache in new week)
Lovastatin, Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin (MOA, Effects, Tox)
Block formation of mevalonate by inhibiting HMG-CoA reductase (results in UPREGULATION OF LDLR)
LDL=big decrease, HLD=mild increase, TG=mild decrease
Hepatotoxicity
Rhabdomyolysis
Niacin (vit. B3) (MOA, Use, Tox)
Inhibits lipolysis in adipose; reduces hepatic VLDL secretion into circulation
LDL=decrease, HDL=Increased, TG=mild decrease
Flushed face (decreased by aspirin or long term use)
Hyperglycemia
Hyperuricemia
Cholestyramine, Colestipol, Colesevelam (MOA, Use, Tox)
Prevent intestinal reabsorption of bile (results in UPREGULATION OF LDLR)
LDL=decrease, HDL=slight increase, TG=slight increase
Terrible taste
GI discomfort
Decrease fat soluble vitamin absorption
Cholesterol gallstones
Ezetimibe (MOA, Use, Tox)
Prevents cholesterol reabsorption at brush border
LDL=decrease
Hepatotoxicity
Diarrhea
Gemfibrozil, Clofibrate, Bezafibrate, Fenofibrate (MOA, Use, Tox)
Upregulate LPL (INCREASED TG CLEARANCE)
LDL=minor decrease, HDL=minor increase, TG=BIG decrease
Myositis
Hepatotoxicity
Cholesterol gallstones
Digoxin (MOA, Use, Tox, Contraindications/Antidote)
Na/K pump inhibition leads to inhibition of Na/Ca exchange and INCREASED INTRACELLULAR Ca (inotropy)
CHF
A-fib (decreased conduction at AV node and depression of SA node)
Cholinergic
ECG - Increase PR, decrease QT, ST scooping, T-wave inversion, Arrhythmia, AV block
Hyperkalemia
Contraindications:
Renal failure (renally excreted)
Hypokalemia (too much digoxin binding)
Quinidine (displaces from binding sites and and decrease clearance)
Antidotes: Slowly normalize K, Lidocaine, Cardiac pacer,
ANTI-DIGOXIN FAB FRAGMENTS, Mg
Antiarrhythmic Drug Classes
“No Bad-Boy Keeps Clean”
Na channel blockers
Beta-Blocker
K channel blockers
Ca channel blockers
Class I Antiarrhythmic Drugs and Class
“Double Quarter Pounder
Lettuce Tomatoes Mayo
Fries Please”
Disopyramide, Quinidine, Procainamide (IA)
Lidocaine, Tocainide, Mexiletine (IB)
Flecainide, Propafenone (IC)
Class IA Antiarrhythmics (Drugs, MOA, Use, Tox)
Quinidine, Procainamide, Disopyramide
Na blocker- Increase AP duration, Increase ERP, Increase QT.
Reentrant and Ectopic tachycardia
Quinidine causes cinchonism (headache & tinnitus)
Procainamide causes SLE-like syndrome
Disopyramide causes thrombocytopenia, TdP
Class IB Antiarrhythmics (Drugs MOA, Use, Tox)
Lidocaine, Mexiletine, Tocainide
Na blocker- Decrease AP duration, Preferentially affect ischemic tissue.
Ventricular arrhythmias, and digitalis-induced arrhythmia
Local anesthetic, CNS, Cardiovascular depression
Class IC Antiarrhythmics (Drugs, MOA, Use, Tox)
Flecainide, Propafenone
Na blocker- Ventricular tachycardias (last resort)
Proarrhythmic (esp post MI), Prolongs refractory period in AV node
Class II Antiarrhythmics (Drugs, MOA, Use, Tox)
Metoprolol, Propranolol, Esmolol, Atenolol, Timolol
Beta-Blockers=Decrease SA and AV nodal activity by decreasing cAMP and Ca currents
Ventricular tachycardia, SVT, Slowing ventricular rate in A-fib
Impotence, Exacerbation of asthma, Sedation/sleep alteration, May mask signs of hypoglycemia
Class III Antiarrhythmics (Drugs, MOA, Use, Tox)
Amiodarone, Sotalol
K blockers= Increase AP duration, Increase ERP, Increase QT (used as last resort)
Amiodarone= Class I, II, III and IV effects (alters lipid membrane), Pulmonary fibrosis, Hepatotoxicity, Hypo/Hyperthyroidism, Photodermatitis, Neuro
Sotalol= TdP, Excessive beta block
Class IV Antiarrhythmics (Drugs, MOA, Use, Tox)
Verapamil, Diltiazem
Ca blockers=Decrease conduction velocity, Increase ERP, Increase PR,
Prevention of nodal arrhythmias (SVT)
Constipation, Edema, CHF, AV block, Sinus node depression)
Adenosine
Hyperpolarize cell
Choice for supraventricular tachycardia (15 sec DOA)
Flushing, Hypotension, Chest pain
Effect blocked by caffeine and theophylline
Mg
Effective in TdP and Digoxin toxicity
Mannitol (Site of action, MOA, Use, Tox)
Proximal tubule
Osmotic diuretic (increase tubular fluid osmolarity, Decreases intracranial pressure)
Drug overdose and Elevated intracranial pressure
Pulmonary edema, Dehydration
CONTRAINDICATED IN ANURIA AND CHF